H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $81 from $80 and keeps a Buy rating on the shares. The company reported a “solid beat and raise quarter,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals price target raised to $95 from $81 at Citizens JMP
- Mirum Pharmaceuticals Reports Strong Q3 2025 Growth
- Mirum Pharmaceuticals: Strong Q3 Performance and Promising Pipeline Drive Buy Rating
- Mirum Pharmaceuticals reports Q3 EPS 5c, consensus (16c)
- Mirum Pharmaceuticals sees FY25 product sales of $500M-$510M, consensus $506.3M